HUTCHMED (China) Limited ADR (HCM)
NASDAQ: HCMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HCM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.30B
- P/E (TTM)
- 132.20
- Forward P/E
- 51.00
- EPS (TTM)
- $0.10
- Dividend yield
- None
- 52-week range
- 9.77 – 16.33
- Day range
- 13.13 – 13.45
- Volume / Avg
- 32.80K / 64.48K
- Beta
- —
- Shares outstanding
- 173.81M
52-week range
HCM stock today
On Nov 20, HCM ended the session at $13.22, shedding $0.23 (1.71%), versus the S&P 500's 3.70% decline. At this level, HCM sits in the middle of its 52-week range of $9.77 to $16.33: 19.0% below the high, set on Jan 16, 2026 and 35.3% above the low. HCM is down 0.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.6%.
HUTCHMED (China) trades at 132.2x its trailing twelve-month earnings per share of $0.10. Its forward P/E of 51.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About HUTCHMED (China)
Company profileHUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Chig Fung Cheng BEc, CA
- Headquarters
- Hong Kong
- Employees
- 1,790
- IPO year
- 2016
- Website
- hutch-med.com
Financial highlights
Full financialsIn fiscal 2025, HUTCHMED (China) generated $548.5 million in revenue, down 13.0% from fiscal 2024, its first annual decline since 2024. Net income was $456.9 million (+1111.0% year over year), for a net margin of 83.3% versus a median of -54.7% in the prior 5 years. Gross margin was 38.7% (down from 44.6%) and operating margin -7.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $548.51M | $630.20M | $838.00M | $426.41M | $356.13M |
| Growth | -12.96% | -24.80% | +96.52% | +19.73% | +56.21% |
| Net income | $456.91M | $37.73M | $100.78M | $-360.83M | $-194.65M |
| EPS (diluted) | $0.52 | $0.04 | $0.12 | $-0.43 | $-0.25 |
Analyst forecast
ForecastConsensus (11 analysts)
none
Avg. price target
$21.14+59.91%
- Strong buy 1
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
HCM news
All HCM news- HUTCHMED (China) Limited Announces China NMPA Approval of SYVIK® and Highlights HMPL-A830 Pre-Clinical DataNasdaq
- HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic AnemiaGlobeNewswire
- HUTCHMED's Cancer Candidate Shows Activity Across KRAS Alterations In Preclinical TestsNasdaqHCM, HEI.A
- HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswire
- HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®Nasdaq
- HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®GlobeNewswire
- HUTCHMED's Sovleplenib Gets FDA Orphan Drug Status For Autoimmune Hemolytic AnemiaNasdaqHCM, UHAL.B
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic AnemiaGlobeNewswire
HUTCHMED (China) peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs HCM |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs HCM |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs HCM |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs HCM |
| NAMSNewAmsterdam Pharma Company N.V. | 18.41 | -5.64% | $2.21B | vs HCM |
| LKFTLakefront Biotherapeutics ADR | 33.31 | -0.24% | $2.18B | vs HCM |
| MBXMBX Biosciences Inc. | 49.55 | -7.23% | $2.46B | vs HCM |
| IDYAIDEAYA Biosciences Inc. | 25.56 | -2.33% | $2.47B | vs HCM |
Indexes, lists and sector
HUTCHMED (China) stock FAQ
What is HUTCHMED (China)'s stock price today?
HCM last traded at $13.22 as of Nov 20, 4:00 PM EST, down 1.71% on the day. Prices are delayed at least 15 minutes.
What is HCM's P/E ratio?
HCM trades at a trailing P/E ratio of 132.20 and a forward P/E of 51.00.
Who is HUTCHMED (China)'s CEO?
Mr. Chig Fung Cheng BEc, CA is the chief executive officer of HUTCHMED (China) Limited ADR, which has about 1,790 employees.
What is the HCM 52-week high?
The 52-week high for HCM is $16.33 and the 52-week low is $9.77. The stock is currently 19.0% below its high.